Live Breaking News & Updates on Initiate Phase

Stay updated with breaking news from Initiate phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

JCR Pharmaceuticals : FY2023 Results Briefing Session -Material-（1,196KB）

JCR Pharmaceuticals : FY2023 Results Briefing Session -Material-（1,196KB）
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Hiroyuki Sonoda , Anne Bechet , Pharmaceuticals Co Ltd , Wave Of Technology Innovation , Research Division , Briefing Session , Initiate Phase , Developmental Pipelines , Acting Officer , General Manager , Latin America , Track Designation , Pediatric Disease Designation , Global Phase , Orphan Drug Designation , Patient First , Technology Innovation , Technological Innovation , Brain Cargo , J Brain Cargo , Gene Therapy ,

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Brianm Strem , University Of California , Kiora Pharmaceuticals , Kiora Pharmaceuticals Inc , Association Of Research , California Newsfile Corp , Open Innovation , Melissa Tosca , Investigational New Drug , Initiate Phase , Private Securities Litigation Reform Act , Annual Report , Current Assets , Release Assets , Current Liabilities , Months Ended March , Fair Value , Common Share , Average Shares Outstanding , Comprehensive Income ,

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Helen Rubinstein , Henry Gosebruch , Exchange Commission , Neumora Therapeutics Inc , Therapeutics Reports First Quarter , Provides Business , Major Depressive Disorder , Fourth Quarter , Initiate Phase , Disease Agitation , Second Quarter , Allosteric Modulator , Advancing Preclinical Work Across , United Kingdom , Neumora Therapeutics , Private Securities Litigation Reform Act , Annual Report , Consolidated Statements ,

Genmab A/S : Interim Report for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024

May 2, 2024 Copenhagen, Denmark;

Interim Report for the First Quarter Ended. ....

Genmab Duobody , Tivdak Genmab , Andrew Carlsen , Informationfor Tivdak , Genmab Abbvie , Marisol Peron , Abbvie Inc , Society Of Gynecologic Oncology , Exchange Commission , Pfizer Inc , European Medicines Agency , Us National Comprehensive Cancer Network , Company Announcement , Medarex Inc , Janssen Biotech Inc , Profoundbio Inc , Pipeline Including Further Development For Approved Medicines , Ministry Of Health , Drug Administration , Halozyme Therapeutics Inc , Global Communications Corporate Affairs , Zai Lab , Genmab Announces Financial Results , First Quarter , First Quarter Ended March , Priority Review ,

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted. ....

United States , United Kingdom , Luis Sanay , Jeffreym Dayno , Idiopathic Hypersomnia Development Program Scheduled For , Paragon Biosciences , European Medicines Agency , Drug Administration , European Union , Zynerba Pharmaceuticals , Exchange Commission , Harmony Biosciences Holdings Inc , Net Revenue , Fourth Quarter , Full Year , Representing Growth , Granted Priority Review , Pediatric Narcolepsy , Orphan Drug Designation , Prader Willi Syndrome , Initiate Phase , First Quarter , Product Revenue Projected Between , Held Today , Biosciences Holdings , Chief Executive Officer ,